Skip to content Skip to footer
Subscribe Now
Post Collaboration Laura Acosta and Himanshu Sehgal in a Candid Conversation
EVENTS

Post Collaboration: Laura Acosta and Himanshu Sehgal in a Candid Conversation

In pursuit of achieving data-driven excellence, PharmaShots came across Newstex. Soon, as a part of a collaboration PharmaShots and Newstex embarked on a journey to delivering high-quality and unerring content. Himanshu Sehgal, Director at PharmaShots, in a candid conversation with Newstex’s Head of Publisher Solutions, Laura Acosta. While sharing the origin story of PharmaShots, Himanshu…
January 11, 2024

Read more

Disease of the Month - Glioblastoma
INSIGHTS+

Disease of the Month – Glioblastoma

Shots:  The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved  For the January edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Glioblastoma, the most…
January 11, 2024

Read more

Announcements

PharmaShots Announces New Content Partnership with Newstex 

PharmaShots is pleased to announce that we have entered into a new content partnership with Newstex, expanding the reach and impact of our insights across global professional and academic audiences.  This collaboration strengthens our mission to deliver high-quality, timely, and actionable biopharma and healthcare intelligence. By integrating PharmaShots’ curated industry updates into Newstex’s premium content distribution network, we aim to support researchers, analysts, students,…
January 11, 2024

Read more

VIEWPOINTS_Michael Moran1_Julie Blaedel2_2024
VIEWPOINTS

Julie Blaedel from Genmab and Michael Moran from AbbVie Discuss the Conditional EC Approval of TEPKINLY in a Stimulating Conversation with PharmaShots

Shots:    Diffuse large B-cell lymphoma remains the most common type of non-Hodgkin lymphoma. With limited therapeutic options for patients whose disease gets relapsed or refractory, AbbVie and Genmab’s TEPKINLY is one-of-a-kind monotherapy for adult patients with relapsed or refractory DLBCL   Post EC’s conditional approval, Julie Blaedel & Michael Moran engage in an enlightening conversation with…
January 10, 2024

Read more

VIEWPOINTS_Brian Quigley_2024
VIEWPOINTS

Tackling Pulmonary Infections: Brian Quigley Sheds Light on Qnovia’s Recent Partnership with the University of Virginia

Shots:  Following Qnovia’s recent partnership with the University of Virginia, Brian Quigley engages in a stimulating conversation with PharmaShots   The collaboration adds two assets, QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection caused by B. anthracis, to Qnovia’s portfolio   During a discussion of Qnovia's proprietary drug delivery platform RespiRx,…
January 8, 2024

Read more

ThoughtSpot_Saurabh Chaubey9
THOUGHTSPOT

Targeted Therapy in Oncology

Shots:  The oncology domain accounts for more than 50% of ongoing clinical trials. The global oncology drug market was valued at $185B in 2022 and is predicted to reach $205B by 2030 with a 13% CAGR   Targeted therapy targets specific genes and proteins to prevent them from growing and spreading. In 2022, the market size…
January 3, 2024

Read more

Insight+_Saurabh Chaubey
INSIGHTS+

Most Viewed Articles of 2023

2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.   Top 20 Radiopharma Companies Based on Market Cap  Shots:  Integrating scintigraphy with…
January 2, 2024

Read more

VIEWPOINTS_Volker Wacheck_2024
VIEWPOINTS

Volker Wacheck Discusses the Approval of the Lonsurf Combination Drug for the Treatment of Colorectal Cancer

Shots:  Volker Wacheck sheds light on the recent approval of Lonsurf in combination with bevacizumab for patients with metastatic colorectal cancer  While sharing key insights from the pivotal P-III (SUNLIGHT) trial evaluating Lonsurf ± bevacizumab, Volker reveals that the combination drug is proven to prolong both OS and PFS along with QoL benefits and a…
January 2, 2024

Read more

Load more